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froBACKGROUND The 2014 Eighth Joint National Committee panel recommendations for management of high blood
pressure (BP) recommend a systolic BP threshold for initiation of drug therapy and a therapeutic target of <150 mm Hg
in those $60 years of age, a departure from prior recommendations of <140 mm Hg. However, it is not known whether
this is an optimal choice, especially for the large population with coronary artery disease (CAD).
OBJECTIVES This study sought to evaluate optimal BP in patients $60 years of age.
METHODS Patients 60 years of age or older with CAD and baseline systolic BP >150 mm Hg randomized to a treatment
strategy on the basis of either atenolol/hydrochlorothiazide or verapamil-SR (sustained release)/trandolapril in INVEST
(INternational VErapamil SR Trandolapril STudy) were categorized into 3 groups on the basis of achieved on-treatment
systolic BP: group 1, <140 mm Hg; group 2, 140 to <150 mm Hg; and group 3, $150 mm Hg. Primary outcome was ﬁrst
occurrence of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke. Secondary outcomes were
all-cause mortality, cardiovascular mortality, total MI, nonfatal MI, total stroke, nonfatal stroke, heart failure, or
revascularization, tabulated separately. Outcomes for each group were compared in unadjusted and multiple propensity
score–adjusted models.
RESULTS Among 8,354 patients included in this analysis with an accumulated 22,308 patient-years of follow-up,
4,787 (57%) achieved systolic BP of <140 mm Hg (group 1), 1,747 (21%) achieved systolic BP of 140 to <150 mm Hg
(group 2), and 1,820 (22%) achieved systolic BP of $150 mm Hg (group 3). In unadjusted models, group 1 had the
lowest rates of the primary outcome (9.36% vs. 12.71% vs. 21.32%; p < 0.0001), all-cause mortality (7.92% vs.
10.07% vs. 16.81%; p < 0.0001), cardiovascular mortality (3.26% vs. 4.58% vs. 7.80%; p < 0.0001), MI (1.07%
vs. 1.03% vs. 2.91%; p < 0.0001), total stroke (1.19% vs. 2.63% vs. 3.85%; p <0.0001), and nonfatal stroke (0.86%
vs 1.89% vs 2.86%; p<0.0001) compared with groups 2 and 3, respectively. In multiple propensity score–adjusted
models, compared with the reference group of <140 mm Hg (group 1), the risk of cardiovascular mortality (adjusted
hazard ratio [HR]: 1.34; 95% conﬁdence interval [CI]: 1.01 to 1.77; p ¼ 0.04), total stroke (adjusted HR: 1.89; 95% CI:
1.26 to 2.82; p ¼ 0.002) and nonfatal stroke (adjusted HR: 1.70; 95% CI: 1.06 to 2.72; p ¼ 0.03) was increased in the
group with BP of 140 to <150 mm Hg, whereas the risk of primary outcome, all-cause mortality, cardiovascular
mortality, total MI, nonfatal MI, total stroke, and nonfatal stroke was increased in the group with BP $150 mm Hg.
CONCLUSIONS In hypertensive patients with CAD who are $60 years of age, achieving a BP target of 140 to <150 mm
Hg as recommended by the JNC-8 panel was associated with less beneﬁt than the previously recommended target
of <140 mm Hg. (J Am Coll Cardiol 2014;64:784–93) © 2014 by the American College of Cardiology Foundation.m the *Division of Cardiology, New York University School of Medicine, New York, New York; yDepartment of Pharmaco-
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785AB BR E V I A T I O N S
AND ACRONYM S
BP = blood pressure
CAD = coronary artery disease
MI = myocardial infarction
= systolic blood pressureT he panel members appointed to the EighthJoint National Committee (JNC-8 panel)recently published recommendations for
the management of high blood pressure (BP) in adults
that recommended a systolic BP (SBP) threshold
$150 mm Hg for initiation of drug therapy and a ther-
apeutic target of <150/90 mm Hg in patients $60
years of age, one of the few “grade A” recommenda-
tions (1). The recommendations state that “setting a
goal SBP of lower than 140 mm Hg in this age group
provides no additional beneﬁt compared with a
higher goal SBP of 140 to 160 mm Hg or 140 to 149
mm Hg” (1). However, 5 of the 17 JNC-8 panel mem-SEE PAGE 794bers did not agree with this viewpoint (2). The
optimal BP for initiation of treatment target and for
use as a therapeutic target in hypertensive
patients $60 years of age is unknown. In HYVET
(Hypertension in the Very Elderly Trial), a study of
patients 80 years of age or older with baseline SBP
of $160 mm Hg, patients randomized to diuretic
agent–based therapy had a signiﬁcant decrease in
stroke, all-cause mortality, cardiovascular mortality,
and heart failure compared with those given placebo
(3). The target SBP in the active-treatment group
was <150 mm Hg, with an achieved systolic pressure
of approximately 144 mm Hg. In addition, there were
fewer serious adverse events in the active-treatment
group than in the placebo group (3).
Because the data regarding the best BP goal among
the elderly are controversial and the 2014 recom-
mendations have not been tested in a cohort of
patients with coronary artery disease (CAD), we
categorized patients $60 years of age with hyper-
tension and CAD enrolled in INVEST (INternational
VErapamil SR Trandolapril STudy) on the basis of
their on-treatment SBP. We sought to assess the
impact of SBP #150 mm Hg compared with lower
achieved SBPs.
METHODS
INVEST, a prospective, randomized, open, blinded-
endpoint trial, involved 22,576 patients 50 years of
age or older with hypertension that required drug
treatment and coexisting CAD. Patients enrolled fromLaboratories, AbbVie, Servier, Medtronic Inc., and Ipca Laboratories Ltd.
relationships relevant to the contents of this paper to disclose.
Listen to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
You can also listen to this issue’s audio summary by JACC Editor-in-Chief D
Manuscript received March 1, 2014; accepted May 15, 2014.14 countries were randomized to a multidrug
antihypertensive strategy on the basis of
either verapamil-SR (sustained-release for-
mulation; n ¼ 11,267) or atenolol (n ¼ 11,309).
Details of the rationale, design, inclusion/
exclusion criteria, and main outcomes were
described previously (4,5). Brieﬂy, the 2
treatment strategies were equivalent for the primary
outcome (ﬁrst occurrence of all-cause death, nonfatal
myocardial infarction [MI], or nonfatal stroke).
Between 1997 and 2003, 61,835 patient-years of
follow-up were accumulated, with a total of 568
patients lost to follow-up for the overall trial.
For this non–pre-speciﬁed post-hoc analysis,
patients $60 years of age with baseline SBP of $150
mm Hg at the time of entry into the trial were chosen.
Patients were randomized to either a verapamil-SR/
trandolapril– or an atenolol/hydrochlorothiazide-
based strategy. Trandolapril and hydrochlorothia-
zide were added if needed for BP control and/or
end-organ protection. In both strategies, trandolapril
was recommended for heart failure, diabetes, or
renal impairment (4,5). Titration of drug and dose
were recommended to achieve the JNC-5/6 BP goals
(<140/90 mm Hg, or <130/85 mm Hg in the pres-
ence of diabetes and/or renal impairment) (6). Each
treatment strategy provided excellent BP control
(>70% of patients achieved BP <140/90 mm Hg
at 24 months) without differences in BP between
the strategies, and therefore, for this analysis, the
2 treatment arms were combined. Patients were
then divided into 3 groups on the basis of achieved
on-treatment SBP: group 1, SBP <140 mm Hg; group 2,
SBP 140 to <150 mm Hg; and group 3, SBP $150
mm Hg.
Data were collected by use of an Internet-based
system, which provided for individualized prescrib-
ing of BP medications using a ﬂexible treatment
algorithm. Follow-up visits were scheduled every
6 weeks for the ﬁrst 6 months and then every
6 months until 2 years after the last patient was
enrolled.
STUDY OUTCOMES. The primary outcome for this
analysis was the ﬁrst occurrence of death (all-cause),
nonfatal MI, or nonfatal stroke. The secondary
outcomes for this analysis were all-cause mortality
SBPAll other authors have reported that they have no
ntin Fuster.
r. Valentin Fuster.
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786(all-cause), cardiovascular mortality, total MI (fatal
and nonfatal), nonfatal MI, total stroke (fatal and
nonfatal), nonfatal stroke, heart failure, and revas-
cularization, considered separately. A 3-member
clinical event committee, blinded to treatment
assignment, adjudicated the outcomes. The deﬁni-
tions of the outcomes have been described previ-
ously (4,7).Baseline Characteristics of the Cohort on the Basis of Achieved On-Trea
Group 1
<140 mm Hg
(n ¼ 4,787)
Group 2
140 to <150 mm Hg
(n ¼ 1,747)
70.1  7.1 71.2  7.1
yrs 45.1 52.4
53.5 57.0
icity
49.8 59.2
American 8.4 12.8
39.6 24.3
ultiracial 2.2 3.7
s index, kg/m2 28.2  7.7 28.8  5.3
Hg 163.5  12.6 165.7  13.3
Hg 91.5  10.7 88.3  11.0
, beats/min 75.8  9.5 75.9  9.8
SR strategy 50.9 49.7
istory
s* 26.8 30.2
olesterolemia* 53.5 56.7
(ever) 42.7 42.6
ial infarction 33.5 33.1
pectoris 71.0 61.9
r PCI 23.7 30.7
r TIA 7.4 8.9
tricular hypertrophy 27.3 21.6
e angina 10.8 12.3
mia 7.8 7.3
ilure (class I to III) 5.9 5.0
12.2 10.8
pairment† 1.6 2.4
3.3 5.1
ing
lent 6.7 8.4
58.8 62.8
31.3 26.3
3.1 2.4
edications
wering agent 34.8 36.3
41.9 31.5
or other antiplatelet agent 59.5 60.2
SAIDs 14.7 16.4
m supplement 4.9 8.8
etic medication§ 21.0 23.2
e replacement 6.7 8.4
ean  SD or %. *History of or currently taking antidiabetic or lipid-lowering medications. †
of skin, prostate, and other cancers with long survival expectancy were not excluded. §Ins
oronary artery bypass graft surgery; DBP ¼ diastolic blood pressure; NSAID ¼ nonsteroidal
¼ peripheral vascular disease; SBP ¼ systolic blood pressure; SR ¼ sustained release; TIA ¼STATISTICAL ANALYSIS. After dividing the cohort
into 3 groups on the basis of on-treatment achieved
SBP, analysis was performed. Baseline characteristics
were compared between the groups by chi-square
test for categorical variables or analysis of variance
for continuous variables. The Kaplan-Meier method
and the log-rank test were used to compare the time
to event among the 3 groups.tment Systolic Pressure
Group 3
$150 mm Hg
(n ¼ 1,820)
All
(n ¼ 8,354) p Value
Multiple PS
Adjusted p Value
71.6  7.6 70.7  7.3 0.001 0.99
53.1 48.3 <0.0001 0.99
59.6 55.6 <0.0001 0.99
56.6 53.2 <0.0001 0.97
19.0 11.6
21.9 32.5
2.4 2.6
28.7  6.7 28.4  7.1 <0.0001 0.99
170.3  16.0 165.4  13.8 <0.0001 0.95
88.9  11.9 90.2  11.1 <0.0001 0.95
75.5  9.9 75.8  9.7 <0.0001 0.99
47.5 49.9 0.05 0.99
33.6 29.0 <0.0001 0.99
55.7 54.7 0.04 0.99
43.2 42.8 0.92 0.99
35.5 33.9 0.24 0.99
62.3 67.2 <0.0001 0.98
30.3 26.6 <0.0001 0.99
9.8 8.3 0.004 0.99
25.8 25.8 <0.0001 0.96
12.8 11.6 0.04 0.99
7.8 7.7 0.78 0.99
7.5 6.1 0.01 0.95
14.0 12.3 0.02 0.98
3.8 2.2 <0.0001 0.96
4.9 4.0 0.001 0.99
6.1 7.0 <0.0001 0.99
58.7 59.6
31.3 30.2
3.8 3.1
32.9 34.7 0.09 0.99
29.8 37.1 <0.0001 0.98
54.9 58.7 0.001 0.99
17.2 15.6 0.03 1.00
9.8 6.8 <0.0001 0.97
26.0 22.5 <0.0001 0.99
9.2 7.6 0.001 0.99
History of or currently have elevated serum creatinine level but <4 mg/dl. ‡Patients
ulin and/or oral hypoglycemic agent.
anti-inﬂammatory agent; PCI ¼ percutaneous coronary intervention; PS ¼ propensity
transient ischemic attack.
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787The 3 groups differed in regard to baseline char-
acteristics (Table 1). To adjust for these baseline dif-
ferences, we used a multiple propensity score
adjustment approach (8). Although propensity score
matching has been used to assemble patient cohorts
that are similar for 2 treatment comparisons, this
approach is problematic when there are more than 2
groups (9). In such cases, a multiple propensity score
approach has been proposed as a solution to the
“dimensionality problem” (8,10).
For this study, a multiple propensity score was
estimated with a nonparsimonious multinomial lo-
gistic regression model with on-treatment achieved
systolic pressure (groups 1, 2, and 3) as the depen-
dent variable and the baseline covariates outlined in
Table 1 as independent variables. The baseline
covariates were then adjusted for the propensity
scores. A Cox proportional hazards model was used
to estimate the effect of comparator groups on the
primary and secondary outcomes after adjustment
for the propensity scores (p1, p2, and p3), their
products (e.g., product of any 2 of the 3 prob-
abilities), and baseline covariates. In a sensitivity
analysis, the primary results were rerun with a
traditional Cox proportional hazards regression
model adjusted to baseline covariates. The group
with on-treatment achieved SBP of <140 mm Hg
was used as the reference. A stepwise Cox propor-
tional hazards model was used to adjust for the
baseline difference with models that included vari-
ables for treatment strategy (verapamil-SR vs.
atenolol), age, race, sex, prior heart failure, and
additional considerations, listed in Table 1, that
were selected if p # 0.20. A p value of <0.05 was
used to denote statistical signiﬁcance. All analyses
were performed with SAS 9.3 (SAS Institute, Cary,
North Carolina).TABLE 2 Event Rates (Unadjusted)
Events
<140 mm Hg
(n ¼ 4,787)
n (%) Rate per 1,000 PY
Primary outcome 448 (9.36) 35.26 222
Death (all-cause) 379 (7.92) 29.56 176
Cardiovascular death 156 (3.26) 12.16 80
Total MI 154 (3.22) 12.06 73
Nonfatal MI 51 (1.07) 3.99 18
Total stroke 57 (1.19) 4.47 46
Nonfatal stroke 41 (0.86) 3.21 33
Revascularization 101 (2.11) 8.00 55
Heart failure (class I to IV) 91 (1.9) 7.15 31
MI ¼ myocardial infarction; PY ¼ patient-years; Total MI ¼ fatal plus nonfatal MI; TotalRESULTS
Among the patients enrolled in INVEST, 8,354
were $60 years of age, had baseline systolic pressure
of at least 150 mm Hg, and fulﬁlled inclusion criteria
for this analysis. At the end of 24 months of follow-
up, 4,787 patients (57%) achieved on-treatment
SBP of <140 mm Hg (group 1); 1,747 patients (21%)
achieved on-treatment SBP of 140 to <150 mm Hg
(group 2); and 1,820 patients (22%) achieved on-
treatment SBP of $150 mm Hg (group 3).
Compared with the group with achieved BP <140
mm Hg (group 1; reference group), the groups with
achieved SBP $140 mm Hg were older; had greater
proportions of women and African Americans;
had a higher prevalence of prior MI, coronary
artery bypass graft surgery, percutaneous coronary
intervention, stroke or transient ischemic attack,
unstable angina, diabetes, renal impairment, hy-
percholesterolemia, and cancer; and had higher
baseline SBP (Table 1). In addition, the groups with
achieved SBP $140 mm Hg were less likely to be
taking nitrates but more likely to be taking
nonsteroidal anti-inﬂammatory drugs other than
aspirin, potassium supplement, antidiabetes medi-
cation, or hormone replacement therapy (Table 1).
After multiple propensity score adjustment, the
differences in baseline characteristics were no
longer signiﬁcant (Table 1). The median and inter-
quartile range for achieved SBP was 131 mm Hg
(126 to 135 mm Hg) in group 1, 144 mm Hg (142
to 146 mm Hg) in group 2, and 158 mm Hg (153 to
166 mm Hg) in group 3.
PRIMARY OUTCOME. For this analysis, a total of
22,308 patient years of follow-up were accumulated.
In the unadjusted model, group 1 had the lowest rate
of the primary outcome compared with the other140 to <150 mm Hg
(n ¼ 1,747)
$150 mm Hg
(n ¼ 1,820)
n (%) Rate per 1,000 PY n (%) Rate per 1,000 PY
(12.71) 44.70 388 (21.32) 83.68
(10.07) 34.91 306 (16.81) 63.62
(4.58) 15.88 142 (7.8) 28.94
(4.18) 14.58 146 (8.02) 30.32
(1.03) 3.59 53 (2.91) 11.01
(2.63) 9.21 70 (3.85) 14.40
(1.89) 6.61 52 (2.86) 28.47
(3.15) 11.12 44 (2.42) 9.11
(1.77) 6.19 45 (2.47) 9.30
stroke ¼ fatal plus nonfatal stroke.
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FIGURE 2 On-Treatment Blood Pressure Categories
and Risk of All-Cause and Cardiovascular Mortality
Cumulative event rate was lowest in the group with achieved
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7882 groups (9.36% vs. 12.71% vs. 21.32%, respectively;
p < 0.0001) (Table 2, Fig. 1). In the multiple propensity
score–adjusted analysis, compared with group 1
(reference group; hazard ratio [HR]: 1.00), the risk of
the primary outcome was no different in group 2
(adjusted HR: 1.12; 95% conﬁdence interval [CI]: 0.95
to 1.32; p ¼ 0.19), but the risk was signiﬁcantly
increased in group 3 (adjusted HR: 1.85; 95% CI: 1.59
to 2.14; p < 0.0001).
SECONDARY OUTCOMES. In the unadjusted model,
group 1 had the lowest rate of all-cause mortality
(7.92% vs. 10.07% vs. 16.81% for groups 1, 2, and 3,
respectively; p < 0.0001) (Table 2, Fig. 2A). In the
multiple propensity score–adjusted analysis, com-
pared with group 1, the mortality risk was no
different in group 2 (adjusted HR: 1.03; 95% CI: 0.86
to 1.24; p ¼ 0.74), but it was substantially increased
in group 3 (adjusted HR: 1.64; 95% CI: 1.40 to 1.93;
p < 0.0001).
In the unadjusted model, group 1 had the lowest
rate of cardiovascular mortality (3.26% vs. 4.58% vs.
7.80% for groups 1, 2, and 3, respectively; p < 0.0001)
(Table 2, Fig. 2B). In the multiple propensity score–
adjusted analysis, compared with group 1, the risk of
cardiovascular mortality was increased in group 2
(adjusted HR: 1.34; 95% CI: 1.01 to 1.77; p ¼ 0.04)
and group 3 (adjusted HR: 2.29; 95% CI: 1.79 to 2.93;
p < 0.0001).
In the unadjusted model, group 1 had the lowest
rate of total MI (fatal and nonfatal; 3.22% vs. 4.18%
vs. 8.02% for groups 1, 2, and 3, respectively;
p < 0.0001) (Table 2). In the multiple propensitysystolic blood pressure (SBP) <140 mm Hg for both all-cause
mortality (A) and cardiovascular (CV) mortality (B).
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FIGURE 1 On-Treatment Blood Pressure Categories
and Risk of Primary Outcome
Cumulative event rate was lowest in the group with achieved
systolic blood pressure (SBP) <140 mm Hg.score–adjusted analysis, compared with group 1,
the risk of MI was no different in group 2 (adjusted
HR: 1.20; 95% CI: 0.90 to 1.60; p ¼ 0.21) but
was substantially increased in group 3 (adjusted
HR: 2.39; 95% CI: 1.87 to 3.05; p < 0.0001).
In the unadjusted model, group 2 had the lowest
rate of nonfatal MI (1.07% vs. 1.03% vs. 2.91% for
groups 1, 2, and 3, respectively; p < 0.0001) (Table 2,
Fig. 3A). In the multiple propensity score–adjusted
analysis, compared with group 1, the risk of MI was
no different in group 2 (adjusted HR: 0.85; 95% CI:
0.49 to 1.46; p ¼ 0.55) but was substantially increased
in group 3 (adjusted HR: 2.45; 95% CI: 1.62 to 3.71;
p < 0.0001).
In the unadjusted model, group 1 had the lowest
rate of total stroke (fatal plus nonfatal; 1.19% vs.
2.63% vs. 3.85% for groups 1, 2, and 3, respectively;
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FIGURE 3 On-Treatment Blood Pressure Categories and Risk of Nonfatal Myocardial Infarction, Total Stroke (Fatal and Nonfatal),
Nonfatal Stroke, Heart Failure, and Revascularization
Cumulative event rate for nonfatal myocardial infarction (A) was lower in the group with achieved systolic blood pressure (SBP) <140 mm Hg
or 140 to <150 mm Hg. For risk of total stroke (B) and nonfatal stroke (C), cumulative event rate was lowest in the group with achieved
SBP <140 mm Hg. For risk of heart failure (D) and risk of revascularization (E), cumulative event rate was similar among the 3 groups. Patients
who achieved SBP <140 mm Hg had the lowest rate of the primary outcome, cardiovascular mortality, and fatal and nonfatal myocardial
infarction compared with the groups with achieved SBP $140 mm Hg.
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789p < 0.0001) (Table 2, Fig. 3B). In the multiple
propensity score–adjusted analysis, compared with
group 1, the risk of total stroke was increased in group
2 (adjusted HR: 1.89; 95% CI: 1.26 to 2.82; p ¼ 0.002)
and group 3 (adjusted HR: 2.93; 95% CI: 2.01 to 4.27;
p < 0.0001).In the unadjusted model, group 1 had the lowest
rate of nonfatal stroke (0.86% vs. 1.89% vs. 2.86% for
groups 1, 2, and 3, respectively; p < 0.0001) (Table 2,
Fig. 3C). In the multiple propensity score–adjusted
analysis, compared with group 1, the risk of nonfatal
stroke was increased in group 2 (adjusted HR: 1.70;
TABLE 3 Adverse Experiences
Type
<140 mm Hg
(n ¼ 4,787)
140 to <150 mm Hg
(n ¼ 1,747)
$150 mm Hg
(n ¼ 1,820) p Value
Alzheimer’s disease 31 (0.6) 11 (0.6) 11 (0.6) 0.98
Angina 189 (3.9) 109 (6.2) 80 (4.4) 0.0004
AV block 21 (0.4) 16 (0.9) 13 (0.7) 0.07
CABG/PCI 257 (5.4) 115 (6.6) 96 (5.3) 0.13
Cancer 167 (3.5) 87 (5.0) 74 (4.1) 0.02
Constipation 76 (1.6) 58 (3.3) 49 (2.7) <0.0001
Cough 153 (3.2) 71 (4.1) 78 (4.3) 0.06
Dizziness 108 (2.3) 68 (3.9) 80 (4.4) <0.0001
Dyspnea 78 (1.6) 45 (2.6) 40 (2.2) 0.03
Gastrointestinal bleeding 76 (1.6) 41 (2.4) 29 (1.6) 0.099
Gout 33 (0.7) 21 (1.2) 24 (1.3) 0.025
Headache 39 (0.8) 33 (1.9) 33 (1.8) 0.0001
Hyperkalemia 4 (0.1) 4 (0.2) 7 (0.4) 0.03
Hypokalemia 11 (0.2) 5 (0.3) 5 (0.3) 0.90
Lightheadedness 38 (0.8) 27 (1.5) 30 (1.6) 0.0027
Liver enzymes out of range 16 (0.3) 10 (0.6) 3 (0.2) 0.11
Parkinson’s disease 9 (0.2) 9 (0.5) 4 (0.2) 0.068
Peripheral edema 31 (0.6) 31 (1.8) 27 (1.5) <0.0001
Peripheral vascular disease 90 (1.9) 41 (2.4) 48 (2.6) 0.13
Renal failure 35 (0.7) 14 (0.8) 23 (1.3) 0.11
Symptomatic bradycardia 83 (1.73) 46 (2.6) 65 (3.6) <0.0001
Unstable angina 108 (2.3) 62 (3.6) 53 (2.9) 0.013
Wheezing 28 (0.6) 14 (0.8) 11 (0.6) 0.61
Values are n (%).
AV ¼ atrioventricular; CABG ¼ coronary artery bypass surgery; PCI ¼ percutaneous coronary intervention.
TABLE 4 Sensitivity
Group 1
(<140 mm Hg) (Re
Group 2
(140 to <150 mm H
Group 3
($150 mm Hg)
CI ¼ conﬁdence interval; H
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79095% CI: 1.06 to 2.72; p ¼ 0.03) and group 3 (adjusted
HR: 2.78; 95% CI: 1.80 to 4.30; p < 0.0001).
In the unadjusted model, the risk of heart failure
was low and similar across the groups (1.90% vs.
1.77% vs. 2.47% for groups 1, 2, and 3, respectively;
p ¼ 0.18) (Table 2, Fig. 3D). Similarly, in the adjusted
analysis, the risk was similar.
In the unadjusted model, the risk of revasculari-
zation was low and similar across the groups
(2.11% vs. 3.15% vs. 2.42% for groups 1, 2, and 3,
respectively; p ¼ 0.21) (Table 2, Fig. 3E). Again, in the
adjusted analysis, the risk was similar.
There were no signiﬁcant increases in adverse ex-
periences in group 1 compared with groups 2 and 3Analysis on the Basis of Traditional Cox Proportional Hazards Regressio
Primary Outcome All-Cause Mortality Cardiovascu
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI
f)
1.00 — 1.00 — 1.00
g)
1.09 (0.93-1.29) 0.27 1.00 (0.83-1.20) 0.99 1.31 (1.00-1.7
1.82 (1.58-2.09) <0.0001 1.60 (1.37-1.86) <0.0001 2.18 (1.73-2.7
R ¼ hazard ratio; MI ¼ myocardial infarction; Ref ¼ reference group.(Table 3). A sensitivity analysis using a Cox propor-
tional hazard regression model for the primary
and secondary outcomes yielded largely similar
results (Table 4).
DISCUSSION
In this post-hoc analysis from INVEST, among
patients $60 years of age with CAD and baseline
SBP $150 mm Hg, those who achieved an SBP <140
mm Hg had the lowest rate of the primary outcome,
all-cause mortality, cardiovascular mortality, total
MI, nonfatal MI, total stroke, and nonfatal stroke in
unadjusted models compared with those in the
groups with achieved SBP $140 mm Hg, without
any increase in adverse experiences (Central
Illustration). Moreover, in the multiple propensity
score–adjusted model, the group with the current
2014 JNC-8 panel–recommended BP target of 140
to <150 mm Hg was associated with an increased
hazard for risk of cardiovascular mortality, total
stroke, and nonfatal stroke compared with the group
with achieved SBP <140 mm Hg.
The recent recommendation, by the majority of
the JNC-8 panel members, of a more relaxed SBP
threshold for initiation of treatment and a target
of <150 mm Hg in patients $60 years of age created
a “tempest in the teapot,” with some members of
the panel disagreeing with the recommendation (2).
Relaxing the BP target in this age group may have
resulted from recent data suggesting that lower
may perhaps not be better when it comes to BP
targets (11–15). However, common themes in most of
these analyses were 2-fold: 1) there was target organ
heterogeneity in that although lower was not better
for cardiac-related outcomes, lower was indeed
better for stroke-related endpoints; 2) the optimal
BP (the nadir BP) with the lowest event rate in
many of these analyses was between 130 and 140
mm Hg. In the ACCORD (Action to Control Cardio-
vascular Risk in Diabetes) trial of patients with
diabetes, targeting an SBP of <120 mm Hg comparedn Model
lar Mortality Total MI Total Stroke
) p Value HR (95% CI) p Value HR (95% CI) p Value
— 1.00 — 1.00 —
3) 0.05 1.14 (087-1.51) 0.34 1.88 (1.27-2.78) 0.002
6) <0.0001 2.23 (1.78-2.81) <0.0001 2.83 (1.98-4.04) <0.0001
Time to Event, y
Log-rank  p<0.0001
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8,345 Patients in INVEST ≥ 60 years
with a baseline systolic BP > 150mmHg
Achieved systolic BP
at follow-up
15
25
35
Systolic BP
<140mmHg
(n = 4,787)
Systolic BP
140-<150mmHg
(n = 1,747)
Systolic BP
≥150mmHg
(n = 1,820)
SBP <140
SBP 140-<150
SBP ≥150
Adverse Outcomes
Fatal and Nonfatal Stroke CV Mortality
CENTRAL ILLUSTRATION Study Design and Main Outcomes
Patients who achieved a systolic blood pressure <140 mm Hg had the lowest rate of the
primary outcome, cardiovascular mortality, and fatal and nonfatal stroke compared with
the groups with achieved systolic blood pressure $140 mm Hg. BP ¼ blood pressure;
CV ¼ cardiovascular; INVEST ¼ INternational VErapamil SR Trandolapril STudy;
MI ¼ myocardial infarction; SBP ¼ systolic blood pressure.
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791with <140 mm Hg did not reduce the rate of a
composite outcome of fatal and nonfatal major
cardiovascular events, although there was a signiﬁ-
cant reduction in the risk of stroke (41% reduction)
at the expense of a signiﬁcant increase in serious
adverse events attributed to antihypertensive
treatment (16). Of note, the mean age in ACCORD
was 62 years. Similarly, in INVEST, tight control of
SBP among patients with diabetes and CAD was not
associated with improved cardiovascular outcomes
compared with usual control (17). Why then did the
panel members choose a target of <150 mm Hg? The
evidence document states that “setting a goal SBP
of lower than 140 mm Hg in this age group provides
no additional beneﬁt compared with a higher goal
SBP of 140 to 160 mm Hg or 140 to 149 mm Hg,” on
the basis of 2 randomized trials in Japanese patients
(18,19). The JATOS (Japanese Trial to Assess Optimal
Systolic Blood Pressure in Elderly Hypertensive
Patients) enrolled patients $65 years of age with
hypertension randomized to strict treatment (targe
<140 mm Hg) versus mild treatment (target 140 to
160 mm Hg) of BP (19). The primary endpoint was
no different between the 2 groups; however, the
test for interaction was signiﬁcant (p ¼ 0.03) for age
such that in those <75 years versus $75 years, there
was a trend toward beneﬁt of the strict treatment
group for primary outcome (2.35 vs. 3.46; p ¼ 0.10),
driven by numerically lower stroke risk (1.33% vs.
2.04%; p ¼ 0.15) (19). The second trial cited by the
document is the VALISH (Valsartan in Elderly Iso-
lated Systolic Hypertension) trial, which enrolled
subjects 70 to 84 years of age with hypertension
randomized to strict BP control (<140 mm Hg)
versus moderate BP control (140 to <150 mm Hg);
there was no statistically signiﬁcant difference in
any of the cardiovascular outcomes (18); however,
as acknowledged by the authors, the analysis was
underpowered to detect a difference (18). Thus, the
evidence to support this 2014 JNC-8 panel grade
A recommendation of a BP target of <150 mm Hg
appears rather weak.
A commentary published by 5 of the 17 members
appointed to the JNC-8 panel rejects the new target
BP, arguing that the evidence does not support this
target and that its liberalization could lead to harmful
consequences, because a large proportion of these
patients have established cardiovascular disease or
are at high risk for cardiovascular disease (including
African Americans and those with multiple risk fac-
tors) (2). This retrospective subgroup analysis de-
monstrated that in hypertensive patients $60 years
of age with CAD who entered the study with BP
>150 mm Hg and who had a protocol-deﬁnedtreatment target of SBP <140 mm Hg, those who
actually achieved the target had numerically lower
rates of primary and secondary outcomes than those
whose on-treatment BP remained higher. A prudent
interpretation of the data suggests that patients $60
years of age with CAD who fail to achieve an on-
treatment SBP of <140 mm Hg have a signiﬁcantly
increased risk of stroke and other adverse out-
comes. Of additional concern, if the U.S. population
demographic resembles that from INVEST, which
is suggested from National Health and Nutrition
PERSPECTIVES
COMPETENCY IN PATIENT CARE: Some patients
greater than 60 years of age who have hypertension
and coronary artery disease may beneﬁt from
lowering systolic blood pressure below 140 mm Hg.
TRANSLATIONAL OUTLOOK: The relative risks and
beneﬁts of more aggressive treatment of hypertension
on cardiovascular outcomes in older patients with cor-
onary artery disease require further study in adequately
powered randomized trials comparing various anti-
hypertensive strategies and target blood pressure levels.
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792Examination Survey data, the new recommendation
places a disproportionately large number of elderly
women and African Americans at increased risk.
However, although the current analysis supports a
target of <140 mm Hg, the data are based on achieved
on-target BP, which is likely inﬂuenced by patients’
baseline characteristics. In addition, the current
analysis was not designed to investigate whether
“lower is better.” Prior analyses from INVEST have
shown a J-curve relationship between BP and car-
diovascular events, such that both a very low and
very high BP were associated signiﬁcantly with
higher event rates (15). Furthermore, for more strin-
gent BP targets such as that in the intensive arm of
the ACCORD trial, trying to achieve a BP <120 mm Hg
may have deleterious consequences, including an
increase in serious adverse events attributed to
antihypertensive treatment.
STUDY LIMITATIONS. This post-hoc analysis from a
randomized trial was not speciﬁcally designed to
test various BP targets. In addition, the results are
applicable only to patients $60 years of age with
known CAD who had SBP >150 mm Hg at entry.
However, patients with CAD are known to be more
susceptible to adverse events with low BP than are
patients without CAD. Although the group with
SBP <140 mm Hg had numerically lower primary and
secondary outcomes, in the multivariable analysis
there was a statistically signiﬁcant difference with
the group with SBP 140 to £150 mm Hg only for the
outcomes of cardiovascular mortality, total stroke,
and stroke, even though the point estimate for the
other outcomes also favored the group with BP <140
mm Hg. The present study was not designed to test
whether patients $60 years of age with SBP of 140 to
150 mm Hg would beneﬁt from antihypertensive
treatment.
CONCLUSIONS
In hypertensive patients $60 years of age with CAD,
an SBP <140 mm Hg is associated with numerically
the lowest rate of primary and most secondarycardiovascular outcomes compared with SBP $140
mm Hg, without any increase in adverse experi-
ences. Moreover, in the multivariable model, when
INVEST patients who achieved on-treatment SBP
<140 mm Hg were compared with those who ach-
ieved on-treatment BP of 140 to 150 mm Hg, the rates
of the overall primary outcome and all-cause mor-
tality were similar. However, patients in the group
with BP <140 mm Hg had signiﬁcantly fewer strokes
and cardiovascular mortality. Patients whose on-
treatment BP remained >150 mm Hg had signiﬁcant
increases in the primary outcome and all secondary
outcomes tested. These data provide important
information to focus the risk-beneﬁt discussion
for patients with on-treatment BP in the 140 to
150 mm Hg range clearly on cardiovascular mortality
and stroke prevention and on overall reduction
of mortality for patients with on-treatment BP
>150 mm Hg.
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